Menkes Disease is referred as kinky hair disorder is an X-linked recessive progressive multiorgan copper metabolism disease. Patients often have a severe clinical history and death in childhood.
Menkes disease is difficult to diagnose early due to mild clinical symptoms and nonspecific laboratory indicators.
Correct diagnosis is critical for optimal care, reducing mortality and morbidity, and for prenatal diagnosis and parental counseling.
Epidemiology
Menkes disease affects around 1 in every 35,000 live male births. In the United States, the prevalence ranges from 1 in 50,000, with novel mutations accounting for one-third of these occurrences. Research completed in Japan between 1993 to 2003 discovered that the incidence of Menkes disease was 1 in every 2.8 million live births. The male live birth rate was found to be 4.9 per million.
Typically, females are carriers; however, instances have been observed owing to rare genetic conditions. The incidence is substantially greater in Australia (1 in 100,000), which may be attributable to the founder impact. Menkes kinky hair disorder has no ethnic or racial predisposition. According to the genetic hypothesis, one-third of Menkes kinky hair disorder cases have novel mutations.
The X-linked recessive trait causes Menkes kinky hair disorder nearly exclusively in males. Females are carriers but rarely show symptoms unless there are certain genetic factors. Menkes kinky hair disorder manifests about six to eight weeks after birth when parents observe delayed development or the appearance of an odd eye or strange limb motions suggestive of seizure activity.
Anatomy
Pathophysiology
Menkes kinky hair disorder directly results from enzyme malfunction or inability to load these enzymes with Cu. When ATP7A fails in the enterocytes, the efflux pump also fails, resulting in excessive Cu buildup in the enterocytes and widespread Cu deficiency. Cytochrome C oxidase, tyrosinase, dopamine beta-hydroxylase, lysyl oxidase, and peptidyl glycine alpha amidating monooxygenase are enzymes that need copper for copper vital metabolic processes.
Cytochrome oxidase deficiency impairs cellular respiration and triggers CNS collapse and ataxia. Autonomic symptoms such as hypothermia and hypotension are caused by irregular catecholamine production caused by dopamine beta-hydroxylase deficiency.
Menkes disease also has significant connective tissue deformities, including joint, skin, and bone abnormalities, and decreased blood vessel reliability due to the lack of lysyl oxidase and faulty collagen and elastin cross-linking. Hair abnormalities and skin hypopigmentation are caused by sulfhydryl oxidase and tyrosinase abnormality, respectively.
Etiology
The underlying problem in copper metabolism in Menkes disease is caused by a mutation in the ATP7A gene discovered on Xq13.3, containing 23 exons. This gene encodes 1500 amino acids and is extensively expressed in tissues such as the lungs, brain, kidneys, and muscles.
In the ATP7A gene, 357 distinct mutations have been discovered, including insertions, deletions, splice, and missense mutations. According to genetic tests, 75% of patients’ mothers are carriers, whereas the remaining 25% are not. There is no apparent link between mutations and clinical outcomes.
As predicted, most patients are men, but a few female cases have also been documented. It is likely the result of X autosome translocation, in which standard X is selectively inactivated. Point mutations and skewed inactivation of the normal X chromosome are two further possibilities.
Genetics
Prognostic Factors
The life expectancy of children with Menkes kinky hair disorder is challenging to predict. However, most of these children die before the age of three.
Pneumonia, which causes respiratory failure, has been identified as a common cause of mortality. However, some deaths occur unexpectedly without a medical reason.
Clinical History
Age group:
Menkes disease usually manifests itself in early infancy, where the symptoms usually start at the age between 2 and 3 months. Diagnosis of the condition is usually done during infancy because the neurological and systemic indicators become more evident.
It also has a speedy progressive neurodegenerative pathway in childhood and is characterized by aggravating developmental delay and neurological disability. In its most severe and classical form, Menkes disease is usually terminal at early childhood where most untreated disease children die at early age- around 3 years old.
Physical Examination
On physical examination, infants with Menkes disease typically appear ill and developmentally delayed, with poor growth and failure to thrive.In severe cases, neuro exam may show hypotonia, inadequate head control, reduced spontaneous motor movements, as well as epileptic seizures. The facial features can be depressed nasal bridge, cherubic and jowly facies. There may be skin and connective tissue abnormalities including skin laxity, joint hypermobility and easy bruising.
Age group
Associated comorbidity
Severe neurodevelopmental delay
Progressive neurodegeneration
Seizures
Hypotonia
Skin laxity
Joint hypermobility
Osteopenia
Recurrent fractures
Arterial tortuosity
Aneurysms
Associated activity
Acuity of presentation
Menkes disease typically presents with a subacute to progressive acuity rather than an abrupt onset. The infants have been affected by the condition tend to be asymptomatic during birth, with the clinical manifestations appearing slowly during the first several months of life, typically between 2 to 3 months of age. The illness after thathas a rapidly progressive coursewith progressive neurodevelopmental delay, hypotonia, seizures, and inability to thrive in infancy. In untreated cases, neurological conditions worsen further resulting in crippling disability and premature death of a child, which mostly occurs at the age of 3.
Differential Diagnoses
Ehlers–Danlos syndrome
Skin laxity and joint hypermobility
Mitochondrial disorders
Laboratory Studies
Imaging Studies
Procedures
Histologic Findings
Staging
Treatment Paradigm
The paradigm of treatment of Menkes disease aims at early diagnosis and timely administration of copper replacement therapy with a view of improving the neurological outcomes and survival.
Parenteral copper supplementation, most frequently copper histidine, which is given by either subcutaneous or intravenous injection, is the primary option as soon as possible in the first few weeks of life before the neurodegeneration becomes irreversible.
In some cases, with early treatment, the activity of copper-dependent enzymes, and the progression of the disease can be slowed (in part), but the response varies according to the severity of the genetic mutation.
Symptomatic care is necessary and supportive, and involves seizure management, nutritional support of feeding disorders and feeding failure, physical and occupational therapy of hypotonia and developmental delay, and vascular, skeletal, and connective tissue complication monitoring.
It is essential that a multidisciplinary strategy with pediatric neurology, genetics, nutrition and rehabilitation be considered. It is also advised to conduct genetic counseling to families affected.
Environmental modification of the Menkes disease is a significant supportive intervention with an aim of decreasing the complications and improving the quality of life. A safe temperature-controlled environment must be provided because the affected infants are likely to experience hypothermia because of autonomic dysfunction. Minimizing injury and fracture through adaptation of the home, studies on soft bedding, handling and excessive stress on joints due to osteopenia and connective tissue fragility are encouraged.
Infants with epilepsy should be provided with seizure-safe measures such as having padded surroundings and be closely supervised. The risk of aspiration should be minimized by optimal feeding environment through proper positioning and aiding feeding methods. Further, the low-infection-risk environment, regular hygiene, and caregiver education about gentle handling, and early identification of complications are also some of the critical elements of environmental modification in Menkes disease.
Effectiveness of Trace Elements in treating Menkes disease
Copper histidine is used as parenteral copper replacement therapy in Menkes disease because intestinal copper absorption is defective. Patients with residual ATP7A activity can have clinical improvement especially with early disease intervention. The therapeutic regimens usually require intravenous or subcutaneous dosing with effective dosing of 350-500 µg of mediation reportedly with a dosage of 350-500 µg being administered daily or alternate days.
role-of-management-in-treating-menkes-disease
The Menkes disease can be treated in several stages reflecting the timing of diagnosis and disease progression. The initial stage is the early detection and early administration of copper replacement therapy preferably during the neonatal stage or within the young infancy to achieve maximum neurological recovery before it is too late.
The acute management stage involves the treatment of active clinical manifestations and entails parenteral copper histidine therapy, seizure control, nutritional support and stabilization of metabolic and neurological conditions. Chronic or maintenance phase implies giving more attention to long-term supportive treatment, with continued copper supplementation in very specific cases, developmental therapy, vascular, skeletal, and connective tissue complications surveillance, and secondary complication prevention, including infections and fractures.
In every stage, the multidisciplinary care and genetic counseling will be involved to deliver the best possible results and help the family that has been affected.
Menkes Disease is referred as kinky hair disorder is an X-linked recessive progressive multiorgan copper metabolism disease. Patients often have a severe clinical history and death in childhood.
Menkes disease is difficult to diagnose early due to mild clinical symptoms and nonspecific laboratory indicators.
Correct diagnosis is critical for optimal care, reducing mortality and morbidity, and for prenatal diagnosis and parental counseling.
Menkes disease affects around 1 in every 35,000 live male births. In the United States, the prevalence ranges from 1 in 50,000, with novel mutations accounting for one-third of these occurrences. Research completed in Japan between 1993 to 2003 discovered that the incidence of Menkes disease was 1 in every 2.8 million live births. The male live birth rate was found to be 4.9 per million.
Typically, females are carriers; however, instances have been observed owing to rare genetic conditions. The incidence is substantially greater in Australia (1 in 100,000), which may be attributable to the founder impact. Menkes kinky hair disorder has no ethnic or racial predisposition. According to the genetic hypothesis, one-third of Menkes kinky hair disorder cases have novel mutations.
The X-linked recessive trait causes Menkes kinky hair disorder nearly exclusively in males. Females are carriers but rarely show symptoms unless there are certain genetic factors. Menkes kinky hair disorder manifests about six to eight weeks after birth when parents observe delayed development or the appearance of an odd eye or strange limb motions suggestive of seizure activity.
Menkes kinky hair disorder directly results from enzyme malfunction or inability to load these enzymes with Cu. When ATP7A fails in the enterocytes, the efflux pump also fails, resulting in excessive Cu buildup in the enterocytes and widespread Cu deficiency. Cytochrome C oxidase, tyrosinase, dopamine beta-hydroxylase, lysyl oxidase, and peptidyl glycine alpha amidating monooxygenase are enzymes that need copper for copper vital metabolic processes.
Cytochrome oxidase deficiency impairs cellular respiration and triggers CNS collapse and ataxia. Autonomic symptoms such as hypothermia and hypotension are caused by irregular catecholamine production caused by dopamine beta-hydroxylase deficiency.
Menkes disease also has significant connective tissue deformities, including joint, skin, and bone abnormalities, and decreased blood vessel reliability due to the lack of lysyl oxidase and faulty collagen and elastin cross-linking. Hair abnormalities and skin hypopigmentation are caused by sulfhydryl oxidase and tyrosinase abnormality, respectively.
The underlying problem in copper metabolism in Menkes disease is caused by a mutation in the ATP7A gene discovered on Xq13.3, containing 23 exons. This gene encodes 1500 amino acids and is extensively expressed in tissues such as the lungs, brain, kidneys, and muscles.
In the ATP7A gene, 357 distinct mutations have been discovered, including insertions, deletions, splice, and missense mutations. According to genetic tests, 75% of patients’ mothers are carriers, whereas the remaining 25% are not. There is no apparent link between mutations and clinical outcomes.
As predicted, most patients are men, but a few female cases have also been documented. It is likely the result of X autosome translocation, in which standard X is selectively inactivated. Point mutations and skewed inactivation of the normal X chromosome are two further possibilities.
The life expectancy of children with Menkes kinky hair disorder is challenging to predict. However, most of these children die before the age of three.
Pneumonia, which causes respiratory failure, has been identified as a common cause of mortality. However, some deaths occur unexpectedly without a medical reason.
Age group:
Menkes disease usually manifests itself in early infancy, where the symptoms usually start at the age between 2 and 3 months. Diagnosis of the condition is usually done during infancy because the neurological and systemic indicators become more evident.
It also has a speedy progressive neurodegenerative pathway in childhood and is characterized by aggravating developmental delay and neurological disability. In its most severe and classical form, Menkes disease is usually terminal at early childhood where most untreated disease children die at early age- around 3 years old.
On physical examination, infants with Menkes disease typically appear ill and developmentally delayed, with poor growth and failure to thrive.In severe cases, neuro exam may show hypotonia, inadequate head control, reduced spontaneous motor movements, as well as epileptic seizures. The facial features can be depressed nasal bridge, cherubic and jowly facies. There may be skin and connective tissue abnormalities including skin laxity, joint hypermobility and easy bruising.
Severe neurodevelopmental delay
Progressive neurodegeneration
Seizures
Hypotonia
Skin laxity
Joint hypermobility
Osteopenia
Recurrent fractures
Arterial tortuosity
Aneurysms
Menkes disease typically presents with a subacute to progressive acuity rather than an abrupt onset. The infants have been affected by the condition tend to be asymptomatic during birth, with the clinical manifestations appearing slowly during the first several months of life, typically between 2 to 3 months of age. The illness after thathas a rapidly progressive coursewith progressive neurodevelopmental delay, hypotonia, seizures, and inability to thrive in infancy. In untreated cases, neurological conditions worsen further resulting in crippling disability and premature death of a child, which mostly occurs at the age of 3.
Ehlers–Danlos syndrome
Skin laxity and joint hypermobility
Mitochondrial disorders
The paradigm of treatment of Menkes disease aims at early diagnosis and timely administration of copper replacement therapy with a view of improving the neurological outcomes and survival.
Parenteral copper supplementation, most frequently copper histidine, which is given by either subcutaneous or intravenous injection, is the primary option as soon as possible in the first few weeks of life before the neurodegeneration becomes irreversible.
In some cases, with early treatment, the activity of copper-dependent enzymes, and the progression of the disease can be slowed (in part), but the response varies according to the severity of the genetic mutation.
Symptomatic care is necessary and supportive, and involves seizure management, nutritional support of feeding disorders and feeding failure, physical and occupational therapy of hypotonia and developmental delay, and vascular, skeletal, and connective tissue complication monitoring.
It is essential that a multidisciplinary strategy with pediatric neurology, genetics, nutrition and rehabilitation be considered. It is also advised to conduct genetic counseling to families affected.
Neurology
Environmental modification of the Menkes disease is a significant supportive intervention with an aim of decreasing the complications and improving the quality of life. A safe temperature-controlled environment must be provided because the affected infants are likely to experience hypothermia because of autonomic dysfunction. Minimizing injury and fracture through adaptation of the home, studies on soft bedding, handling and excessive stress on joints due to osteopenia and connective tissue fragility are encouraged.
Infants with epilepsy should be provided with seizure-safe measures such as having padded surroundings and be closely supervised. The risk of aspiration should be minimized by optimal feeding environment through proper positioning and aiding feeding methods. Further, the low-infection-risk environment, regular hygiene, and caregiver education about gentle handling, and early identification of complications are also some of the critical elements of environmental modification in Menkes disease.
Neurology
Copper histidine is used as parenteral copper replacement therapy in Menkes disease because intestinal copper absorption is defective. Patients with residual ATP7A activity can have clinical improvement especially with early disease intervention. The therapeutic regimens usually require intravenous or subcutaneous dosing with effective dosing of 350-500 µg of mediation reportedly with a dosage of 350-500 µg being administered daily or alternate days.
Neurology
The Menkes disease can be treated in several stages reflecting the timing of diagnosis and disease progression. The initial stage is the early detection and early administration of copper replacement therapy preferably during the neonatal stage or within the young infancy to achieve maximum neurological recovery before it is too late.
The acute management stage involves the treatment of active clinical manifestations and entails parenteral copper histidine therapy, seizure control, nutritional support and stabilization of metabolic and neurological conditions. Chronic or maintenance phase implies giving more attention to long-term supportive treatment, with continued copper supplementation in very specific cases, developmental therapy, vascular, skeletal, and connective tissue complications surveillance, and secondary complication prevention, including infections and fractures.
In every stage, the multidisciplinary care and genetic counseling will be involved to deliver the best possible results and help the family that has been affected.
Menkes Disease is referred as kinky hair disorder is an X-linked recessive progressive multiorgan copper metabolism disease. Patients often have a severe clinical history and death in childhood.
Menkes disease is difficult to diagnose early due to mild clinical symptoms and nonspecific laboratory indicators.
Correct diagnosis is critical for optimal care, reducing mortality and morbidity, and for prenatal diagnosis and parental counseling.
Menkes disease affects around 1 in every 35,000 live male births. In the United States, the prevalence ranges from 1 in 50,000, with novel mutations accounting for one-third of these occurrences. Research completed in Japan between 1993 to 2003 discovered that the incidence of Menkes disease was 1 in every 2.8 million live births. The male live birth rate was found to be 4.9 per million.
Typically, females are carriers; however, instances have been observed owing to rare genetic conditions. The incidence is substantially greater in Australia (1 in 100,000), which may be attributable to the founder impact. Menkes kinky hair disorder has no ethnic or racial predisposition. According to the genetic hypothesis, one-third of Menkes kinky hair disorder cases have novel mutations.
The X-linked recessive trait causes Menkes kinky hair disorder nearly exclusively in males. Females are carriers but rarely show symptoms unless there are certain genetic factors. Menkes kinky hair disorder manifests about six to eight weeks after birth when parents observe delayed development or the appearance of an odd eye or strange limb motions suggestive of seizure activity.
Menkes kinky hair disorder directly results from enzyme malfunction or inability to load these enzymes with Cu. When ATP7A fails in the enterocytes, the efflux pump also fails, resulting in excessive Cu buildup in the enterocytes and widespread Cu deficiency. Cytochrome C oxidase, tyrosinase, dopamine beta-hydroxylase, lysyl oxidase, and peptidyl glycine alpha amidating monooxygenase are enzymes that need copper for copper vital metabolic processes.
Cytochrome oxidase deficiency impairs cellular respiration and triggers CNS collapse and ataxia. Autonomic symptoms such as hypothermia and hypotension are caused by irregular catecholamine production caused by dopamine beta-hydroxylase deficiency.
Menkes disease also has significant connective tissue deformities, including joint, skin, and bone abnormalities, and decreased blood vessel reliability due to the lack of lysyl oxidase and faulty collagen and elastin cross-linking. Hair abnormalities and skin hypopigmentation are caused by sulfhydryl oxidase and tyrosinase abnormality, respectively.
The underlying problem in copper metabolism in Menkes disease is caused by a mutation in the ATP7A gene discovered on Xq13.3, containing 23 exons. This gene encodes 1500 amino acids and is extensively expressed in tissues such as the lungs, brain, kidneys, and muscles.
In the ATP7A gene, 357 distinct mutations have been discovered, including insertions, deletions, splice, and missense mutations. According to genetic tests, 75% of patients’ mothers are carriers, whereas the remaining 25% are not. There is no apparent link between mutations and clinical outcomes.
As predicted, most patients are men, but a few female cases have also been documented. It is likely the result of X autosome translocation, in which standard X is selectively inactivated. Point mutations and skewed inactivation of the normal X chromosome are two further possibilities.
The life expectancy of children with Menkes kinky hair disorder is challenging to predict. However, most of these children die before the age of three.
Pneumonia, which causes respiratory failure, has been identified as a common cause of mortality. However, some deaths occur unexpectedly without a medical reason.
Age group:
Menkes disease usually manifests itself in early infancy, where the symptoms usually start at the age between 2 and 3 months. Diagnosis of the condition is usually done during infancy because the neurological and systemic indicators become more evident.
It also has a speedy progressive neurodegenerative pathway in childhood and is characterized by aggravating developmental delay and neurological disability. In its most severe and classical form, Menkes disease is usually terminal at early childhood where most untreated disease children die at early age- around 3 years old.
On physical examination, infants with Menkes disease typically appear ill and developmentally delayed, with poor growth and failure to thrive.In severe cases, neuro exam may show hypotonia, inadequate head control, reduced spontaneous motor movements, as well as epileptic seizures. The facial features can be depressed nasal bridge, cherubic and jowly facies. There may be skin and connective tissue abnormalities including skin laxity, joint hypermobility and easy bruising.
Severe neurodevelopmental delay
Progressive neurodegeneration
Seizures
Hypotonia
Skin laxity
Joint hypermobility
Osteopenia
Recurrent fractures
Arterial tortuosity
Aneurysms
Menkes disease typically presents with a subacute to progressive acuity rather than an abrupt onset. The infants have been affected by the condition tend to be asymptomatic during birth, with the clinical manifestations appearing slowly during the first several months of life, typically between 2 to 3 months of age. The illness after thathas a rapidly progressive coursewith progressive neurodevelopmental delay, hypotonia, seizures, and inability to thrive in infancy. In untreated cases, neurological conditions worsen further resulting in crippling disability and premature death of a child, which mostly occurs at the age of 3.
Ehlers–Danlos syndrome
Skin laxity and joint hypermobility
Mitochondrial disorders
The paradigm of treatment of Menkes disease aims at early diagnosis and timely administration of copper replacement therapy with a view of improving the neurological outcomes and survival.
Parenteral copper supplementation, most frequently copper histidine, which is given by either subcutaneous or intravenous injection, is the primary option as soon as possible in the first few weeks of life before the neurodegeneration becomes irreversible.
In some cases, with early treatment, the activity of copper-dependent enzymes, and the progression of the disease can be slowed (in part), but the response varies according to the severity of the genetic mutation.
Symptomatic care is necessary and supportive, and involves seizure management, nutritional support of feeding disorders and feeding failure, physical and occupational therapy of hypotonia and developmental delay, and vascular, skeletal, and connective tissue complication monitoring.
It is essential that a multidisciplinary strategy with pediatric neurology, genetics, nutrition and rehabilitation be considered. It is also advised to conduct genetic counseling to families affected.
Neurology
Environmental modification of the Menkes disease is a significant supportive intervention with an aim of decreasing the complications and improving the quality of life. A safe temperature-controlled environment must be provided because the affected infants are likely to experience hypothermia because of autonomic dysfunction. Minimizing injury and fracture through adaptation of the home, studies on soft bedding, handling and excessive stress on joints due to osteopenia and connective tissue fragility are encouraged.
Infants with epilepsy should be provided with seizure-safe measures such as having padded surroundings and be closely supervised. The risk of aspiration should be minimized by optimal feeding environment through proper positioning and aiding feeding methods. Further, the low-infection-risk environment, regular hygiene, and caregiver education about gentle handling, and early identification of complications are also some of the critical elements of environmental modification in Menkes disease.
Neurology
Copper histidine is used as parenteral copper replacement therapy in Menkes disease because intestinal copper absorption is defective. Patients with residual ATP7A activity can have clinical improvement especially with early disease intervention. The therapeutic regimens usually require intravenous or subcutaneous dosing with effective dosing of 350-500 µg of mediation reportedly with a dosage of 350-500 µg being administered daily or alternate days.
Neurology
The Menkes disease can be treated in several stages reflecting the timing of diagnosis and disease progression. The initial stage is the early detection and early administration of copper replacement therapy preferably during the neonatal stage or within the young infancy to achieve maximum neurological recovery before it is too late.
The acute management stage involves the treatment of active clinical manifestations and entails parenteral copper histidine therapy, seizure control, nutritional support and stabilization of metabolic and neurological conditions. Chronic or maintenance phase implies giving more attention to long-term supportive treatment, with continued copper supplementation in very specific cases, developmental therapy, vascular, skeletal, and connective tissue complications surveillance, and secondary complication prevention, including infections and fractures.
In every stage, the multidisciplinary care and genetic counseling will be involved to deliver the best possible results and help the family that has been affected.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Digital Certificate PDF
On course completion, you will receive a full-sized presentation quality digital certificate.
medtigo Simulation
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
medtigo Points
medtigo points is our unique point redemption system created to award users for interacting on our site. These points can be redeemed for special discounts on the medtigo marketplace as well as towards the membership cost itself.
Community Forum post/reply = 5 points
*Redemption of points can occur only through the medtigo marketplace, courses, or simulation system. Money will not be credited to your bank account. 10 points = $1.
All Your Certificates in One Place
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
